Alexandru Eniu
YOU?
Author Swipe
View article: EVALUATING BARRIERS AND OPPORTUNITIES IN ADVANCED BREAST CANCER CARE: INSTITUTIONAL CAPACITY ASSESSMENTS IN 16 LOW- AND MIDDLE-INCOME COUNTRIES
EVALUATING BARRIERS AND OPPORTUNITIES IN ADVANCED BREAST CANCER CARE: INSTITUTIONAL CAPACITY ASSESSMENTS IN 16 LOW- AND MIDDLE-INCOME COUNTRIES Open
View article: Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 9)
Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025–2035 (Goal 9) Open
Advanced breast cancer (ABC) remains an incurable yet treatable disease, requiring lifelong care. While treatment advancements have extended survival for many patients, access to these innovations is far from universal. There remains a cri…
View article: Impact of BRCA Status on Reproductive Outcomes in Breast Cancer Patients in Romania: A Retrospective Study
Impact of BRCA Status on Reproductive Outcomes in Breast Cancer Patients in Romania: A Retrospective Study Open
Background: Breast cancer is the most frequently diagnosed cancer in women, and advances in genetic screening have led to a growing number of patients being identified as BRCA mutation carriers. For these women, the safety of pregnancy fol…
View article: Impact of BRCA Status on Reproductive Outcomes in Breast Cancer Patients in Romania: A Retrospective Study
Impact of BRCA Status on Reproductive Outcomes in Breast Cancer Patients in Romania: A Retrospective Study Open
Background Breast cancer is the most common malignancy among women and more female patients fall within genetic testing guidelines indications. Therefore, a larger number of patients will be identified as BRCA mutation carriers. Conflictin…
View article: P242: Global disparities in breast cancer treatment – an international survey
P242: Global disparities in breast cancer treatment – an international survey Open
View article: 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) Open
View article: Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training From ASCO
Envisioning Academic Global Oncologists: Proposed Competencies for Global Oncology Training From ASCO Open
Recognizing the rising incidence, prevalence, and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has committed to expanding its engagement at a global lev…
View article: Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes Open
Background Trastuzumab has had a major impact on the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Anti-HER2 biosimilars such as Ogivri have demonstrated safety and clinical equivalence to trastu…
View article: Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes (Preprint)
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes (Preprint) Open
BACKGROUND Trastuzumab has had a major impact on the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Anti-HER2 biosimilars such as Ogivri have demonstrated safety and clinical equivalence to trast…
View article: Allocation of authorship and patient enrollment among global clinical trials in oncology
Allocation of authorship and patient enrollment among global clinical trials in oncology Open
Background Oncology randomized controlled trials (RCTs) are increasingly global in scope. Whether authorship is equitably shared between investigators from high‐income countries (HIC) and low‐middle/upper‐middle incomes countries (LMIC/UMI…
View article: 75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy
75P Electronic patient-reported outcomes and machine learning in predicting unplanned visits and hospitalisation rates in cancer patients undergoing systemic therapy Open
Electronic patient-reported outcomes (ePRO) have shown the potential to improve clinical practice for cancer patients. The collection of ePRO via smartphone apps is becoming more wide-spread. Such data, comprising of symptom and diary entr…
View article: Precision medicine in early breast cancer—beginning of a successful story?
Precision medicine in early breast cancer—beginning of a successful story? Open
View article: Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials Led by High-Income Countries
Participation of Lower and Upper Middle–Income Countries in Oncology Clinical Trials Led by High-Income Countries Open
Importance Many randomized clinical trials (RCTs) led by high-income countries (HICs) now enroll patients from lower middle–income countries (LMICs) and upper middle–income countries (UMICs). Although enrolling diverse populations promotes…
View article: Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer
Current challenges and unmet needs in treating patients with human epidermal growth factor receptor 2-positive advanced breast cancer Open
View article: Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic
Changing the landscape of European School of Oncology–European Society for Medical Oncology masterclasses in clinical oncology during the COVID-19 pandemic Open
Aims: This study aimed to assess the participants' evaluation of the European School of Oncology-European Society for Medical Oncology virtual masterclasses in clinical oncology (MCOs) organized during the pandemic in 2021. Mater…
View article: Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients
Spectrum of BRCA1/2 Mutations in Romanian Breast and Ovarian Cancer Patients Open
Background: About 10,000 women are diagnosed with breast cancer and about 2000 women are diagnosed with ovarian cancer each year in Romania. There is an insufficient number of genetic studies in the Romanian population to identify patients…
View article: Eusoma/Abc Global Alliance Quality Indicators for Metastatic Breast Cancer Care
Eusoma/Abc Global Alliance Quality Indicators for Metastatic Breast Cancer Care Open
View article: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Open
View article: 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)
4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4) Open
Advanced Breast Cancer (ABC) comprises both locally advanced breast cancer (LABC) and metastatic breast cancer (MBC) [1]. Although treatable, MBC remains virtually an incurable disease with a median overall survival (OS) of 3 years and a 5…
View article: THE ABC OF VACCINATION FOR ADVANCED BREAST CANCER PATIENTS
THE ABC OF VACCINATION FOR ADVANCED BREAST CANCER PATIENTS Open
View article: Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial Open
Purpose Equivalent efficacy was demonstrated for the biosimilar CT-P6 and trastuzumab following neoadjuvant therapy for patients with human epidermal growth factor receptor-2 (HER2)-positive early breast cancer. Following adjuvant treatmen…
View article: A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis Open
View article: Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto Open
View article: Expert Discussion: ASCO 2021
Expert Discussion: ASCO 2021 Open
View article: Recommendations from the ASCO Academic Global Oncology Task Force
Recommendations from the ASCO Academic Global Oncology Task Force Open
In recognition of the rising incidence and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has prioritized efforts to enhance its engagement at a global le…
View article: 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Open
View article: The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview
The Breast Health Global Initiative 2018 Global Summit on Improving Breast Healthcare Through Resource‐Stratified Phased Implementation: Methods and overview Open
Background The Breast Health Global Initiative (BHGI) established a series of resource‐stratified, evidence‐based guidelines to address breast cancer control in the context of available resources. Here, the authors describe methodologies a…
View article: The global burden of women’s cancers: a grand challenge in global health
The global burden of women’s cancers: a grand challenge in global health Open
Every year, more than 2 million women worldwide are diagnosed with breast or cervical cancer, yet where a woman lives, her socioeconomic status, and agency largely determines whether she will develop one of these cancers and will ultimatel…
View article: Enhancing global access to cancer medicines
Enhancing global access to cancer medicines Open
Globally, cancer is the second leading cause of death, with numbers greatly exceeding those for human immunodeficiency virus/acquired immunodeficiency syndrome, tuberculosis, and malaria combined. Limited access to timely diagnosis, to aff…
View article: Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial
Efficacy and safety of CT-P6 versus reference trastuzumab in HER2-positive early breast cancer: updated results of a randomised phase 3 trial Open